Nachrichten zur Regeneron Pharmaceuticals Inc. Aktie

2seventy Bio, Regeneron in Amended Collaboration >TSVT REGN

2seventy Bio, Regeneron in Amended Collaboration >TSVT REGN...…

Insiderhandel: EVP Commercial verkauft Aktien von Regeneron Pharmaceuticals im Wert von 794.046$

Mccourt, Marion - Vorstand - Tag der Transaktion: 2023-01-03...…

Sensei Biotherapeutics Enters Clinical Supply Agreement With Regeneron For Libtayo

WASHINGTON (dpa-AFX) - Sensei Biotherapeutics, Inc. (SNSE) announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo. The…

Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors

BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the…

Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023

TARRYTOWN, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will…

Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 4.111.822$

Coles, N Anthony - Aufsichtsrat - Tag der Transaktion: 2022-12-28...…

Regeneron Granted Marketing Authorization For Libtayo In Japan For Recurrent Cervical Cancer

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the Ministry of Health, Labor and Welfare in Japan has granted marketing and…

Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer

TARRYTOWN, N.Y., Dec. 23, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) today announced that the Ministry of Health, Labor and…

Regeneron: Positive Dupixent Phase 3 Results In Eosinophilic Esophagitis Published

PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said that the New England Journal of Medicine has published results…

Form 8-K REGENERON PHARMACEUTICAL For: Dec 19

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y., Dec. 19, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 41st Annual…

Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

The CHMP recommends approval of Sanofi (SNY) and partner Regenerons Dupixent for the treatment of adults and adolescents with eosinophilic…

Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a…

Regeneron: CHMP Recommends Dupixent For EU Approval To Treat Eosinophilic Esophagitis

PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi (SNY) announced Friday that the European Medicines Agencys…

Regeneron, Sanofi Get CHMP Backing for Dupixent in Eosinophilic Esophagitis

Regeneron, Sanofi Get CHMP Backing for Dupixent in Eosinophilic Esophagitis...…

Sanofi, Regeneron Dupixent gets approval in EU for expanded use in skin disorder

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron, Sanofi: Dupixent Approved In EU For Prurigo Nodularis

PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi (SNY) announced Thursday that the European Commission has…

Regeneron (REGN) Presents Positive Data on MM and FL Drugs

Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH....…

Regeneron Reveals An Early Cut Data From Follicular Lymphoma Study At ASH Meeting

Regeneron Pharma Announces Positive Data From Mid-stage Study Of Linvoseltamab

WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) Monday announced positive initial data from a pivotal Phase 2 expansion cohort evaluating…

Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year

DJSI World recognizes the top 10 percent of most sustainable companies by industry; Regeneron ranked among top three biotechnology companies1…

UK drug regulator warns of eye-related side effects after Sanofi/Regeneron Dupixent therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron wins FDA priority review for label expansion of dyslipidemia therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ISA Pharmaceuticals Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

Study designed to investigate the efficacy and safety of ISA101b added to checkpoint inhibitor therapy in Human Papilloma Virus type…

Insiderhandel: EVP & General Mgr, Industrial verkauft Aktien von Regeneron Pharmaceuticals im Wert von 8.868.260$

Van Plew Daniel P. - Vorstand - Tag der Transaktion: 2022-11-23...…

Regeneron-Aktie: Stürzt der Highflyer bald wieder ab?

Die Aktie von Regeneron Pharmaceuticals (WKN: 881535) ist ein Highflyer aus dem US-Biotech-Sektor und zuletzt meldete das Unternehmen wieder starke…

Regeneron :EC Oks Libtayo As First Immunotherapy In Second Line Recurrent/Metastatic Cervical Cancer

WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) said that the European Commission approved Libtayo (cemiplimab) as monotherapy for the treatment…

Severe Asthma Digital Marketing Trends Report 2022 Featuring Sanofi, Regeneron, Genentech, Novartis, GSK, AstraZeneca, Amgen, & Teva

DUBLIN, Nov. 21, 2022 /PRNewswire/ -- The "Digital Marketing Trends in Severe Asthma" report has been added to ResearchAndMarkets.coms offering.…

CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron

CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies....…

CytomX Therapeutics Shares Rally on Regeneron Pact

CytomX Therapeutics Shares Rally on Regeneron Pact...…

Regeneron, CytomX Set Cancer-Therapy Collaboration >REGN CTMX

Regeneron, CytomX Set Cancer-Therapy Collaboration >REGN CTMX...…

Grey Wolf Therapeutics Announces Clinical Supply Agreement with Regeneron for Trial Evaluating GRWD5769 in Combination with Libtayo® (cemiplimab)

Combination of First-in-Class ERAP1 Inhibitor and Anti-PD-1 Monoclonal Antibody to be Studied in Patients with a Range of Advanced Solid…

Regeneron, Sanofi: CHMP Recommends Approval Of Dupixent In The EU

PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced that the European Medicines Agencys Committee for Medicinal Products for…

Regeneron, Sanofi Get CHMP Backing for Dupixent in Prurigo Nodularis >REGN SNY

Regeneron, Sanofi Get CHMP Backing for Dupixent in Prurigo Nodularis >REGN SNY...…

Regeneron pares gains after PTAB rules against Eylea patent

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 20

CAMBRIDGE, Mass., Nov. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Regeneron, Bayer Offer More Promising Data for Aging Eye Drug

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Supreme Court to hear Amgen appeal on Repatha spat with Sanofi, Regeneron

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent

Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from…

Form 10-Q REGENERON PHARMACEUTICAL For: Sep 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron Q3 sales sans COVID products grow on back of blockbuster Eylea

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron Pharmaceuticals Q3 Profit Decreases, but beats estimates

WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced earnings for third quarter that decreased from the same period last year but…

Regeneron Pharmaceuticals Q3 tops earnings and revenue marks

Regeneron Pharmaceuticals Inc. said Thursday its third-quarter net income fell 19% to $1.32 billion or $11.66 a share, from…

Can Regeneron maintain EPS beat run in Q3 as eye care space heats up?

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Final Trades: Boeing, Amazon, Regeneron & more

The "Halftime Report" traders give their top picks to watch for the second half....…

Regeneron Pharmaceuticals: Downgrade

St. Petersburg (www.aktiencheck.de) - Rating-Update: Dane Leone, Analyst von Raymond James, stuft die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075,…

Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award

Inmazeb is the first FDA-approved treatment for Zaire ebolavirus TARRYTOWN, N.Y., Oct. 28, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:…

dpa-AFX ProFeed